Fund L.P. 10X Sells 10,000 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) major shareholder Fund L.P. 10X sold 10,000 shares of Galectin Therapeutics stock in a transaction on Tuesday, January 11th. The shares were sold at an average price of $2.10, for a total transaction of $21,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Fund L.P. 10X also recently made the following trade(s):

  • On Thursday, December 2nd, Fund L.P. 10X sold 10,000 shares of Galectin Therapeutics stock. The stock was sold at an average price of $2.37, for a total transaction of $23,700.00.
  • On Monday, November 1st, Fund L.P. 10X sold 10,000 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.19, for a total value of $31,900.00.
  • On Friday, October 15th, Fund L.P. 10X sold 10,000 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.37, for a total value of $33,700.00.

NASDAQ:GALT opened at $2.02 on Friday. The company has a quick ratio of 4.58, a current ratio of 4.58 and a debt-to-equity ratio of 2.76. Galectin Therapeutics Inc. has a 52-week low of $1.82 and a 52-week high of $5.70. The stock has a fifty day simple moving average of $2.42 and a 200-day simple moving average of $3.05.

Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Monday, November 15th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. As a group, research analysts predict that Galectin Therapeutics Inc. will post -0.59 EPS for the current year.

A number of hedge funds have recently made changes to their positions in GALT. Rockefeller Capital Management L.P. raised its stake in Galectin Therapeutics by 419.3% in the 2nd quarter. Rockefeller Capital Management L.P. now owns 10,386 shares of the company’s stock valued at $33,000 after purchasing an additional 8,386 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in Galectin Therapeutics in the 2nd quarter valued at about $539,000. Susquehanna Fundamental Investments LLC acquired a new position in Galectin Therapeutics in the 2nd quarter valued at about $50,000. Ergoteles LLC acquired a new position in Galectin Therapeutics in the 2nd quarter valued at about $445,000. Finally, XTX Topco Ltd acquired a new position in Galectin Therapeutics in the 2nd quarter valued at about $40,000. 12.28% of the stock is owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research downgraded Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments.

Recommended Story: What does a neutral rating on stocks mean?

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.